http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries
-
Greenwich LifeSciences (GLSI) Announces Flamingo-01 Manufacturing & Protocol Accepted by EU Regulators
-
Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators
-
Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators
-
Greenwich LifeSciences (GLSI) Provides Update on Phase III Trial
-
Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01
-
Greenwich LifeSciences (GLSI) Extends Lock-up of Directors and Officers to End of 2024
-
Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024
-
Greenwich LifeSciences (GLSI) Issues Year End Update
-
Greenwich LifeSciences Provides Year End Update
-
Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023
-
Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial
-
Greenwich LifeSciences (GLSI) Provides Updates on Flamingo-01 Phase III Clinical Trial
-
Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial
-
Greenwich LifeSciences Provides Financing Strategy & Corporate Update
-
Greenwich LifeSciences (GLSI) Resumes $4.5M Share Buyback
-
Greenwich LifeSciences to Resume Stock Repurchase Program
-
Greenwich LifeSciences (GLSI) Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting
-
Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting
-
Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences
-
Greenwich LifeSciences (GLSI) Presents Phase IIb Data Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer
-
Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer
-
Greenwich LifeSciences (GLSI) Issues Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting
-
Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting
-
Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference
-
Greenwich LifeSciences (GLSI) Announces Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
-
Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
-
Greenwich LifeSciences (GLSI) Announces $10M Share Buyback, Extends Insider Lock-Up for 1 Extra Year
-
Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year
-
Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster
-
Greenwich LifeSciences (GLSI) Reports 5 Year Data for GP2 Phase IIb Clinical Trial, Reveals Potential For New T Cell Platform Technology
-
Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology
-
Greenwich LifeSciences to Participate in Multiple Interviews and Conferences
-
Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial
-
Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2
-
Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report
-
Greenwich LifeSciences to Participate in Jefferies’ 12th Annual London Healthcare Conference
-
Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference
-
Greenwich LifeSciences (GLSI) Issues Clinical Update on Upcoming Phase III Trial, FLAMINGO-01
-
Greenwich LifeSciences Provides Clinical Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
-
Greenwich LifeSciences Provides Updated Corporate Presentation and Webcasts
-
Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston
-
Greenwich LifeSciences to Present at the Benzinga Healthcare Small Cap Conference
-
Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference
-
Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference
-
Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments
-
Greenwich LifeSciences to Participate in Citi’s 16th Annual Biopharma Virtual Conference
-
Greenwich LifeSciences Set to Join Russell 2000® Index
-
Greenwich LifeSciences (GLSI) Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021
-
Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming that GP2 Treatment to Prevent Metastatic Breast Cancer Recurrence is Well Tolerated
